176 related articles for article (PubMed ID: 12880373)
21. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
[TBL] [Abstract][Full Text] [Related]
22. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.
Steidler L; Hans W; Schotte L; Neirynck S; Obermeier F; Falk W; Fiers W; Remaut E
Science; 2000 Aug; 289(5483):1352-5. PubMed ID: 10958782
[TBL] [Abstract][Full Text] [Related]
23. [Unraveling the Pathogenesis of Inflammatory Bowel Disease and Search for New Therapeutic Medicines].
Hayashi S
Yakugaku Zasshi; 2020; 140(2):123-128. PubMed ID: 32009032
[TBL] [Abstract][Full Text] [Related]
24. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
[TBL] [Abstract][Full Text] [Related]
25. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.
Caradonna L; Amati L; Magrone T; Pellegrino NM; Jirillo E; Caccavo D
J Endotoxin Res; 2000; 6(3):205-14. PubMed ID: 11052175
[TBL] [Abstract][Full Text] [Related]
26. Bacterial induction of proinflammatory cytokines in inflammatory bowel disease.
Klapproth JM; Sasaki M
Inflamm Bowel Dis; 2010 Dec; 16(12):2173-9. PubMed ID: 20848533
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease.
Cominelli F; Pizarro TT
Aliment Pharmacol Ther; 1996; 10 Suppl 2():49-53; discussion 54. PubMed ID: 8899101
[TBL] [Abstract][Full Text] [Related]
28. Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin.
Bertrand V; Quéré S; Guimbaud R; Sogni P; Chauvelot-Moachon L; Tulliez M; Lamarque D; Charreire J; Giroud JP; Couturier D; Chaussade S; Breban M
Eur Cytokine Netw; 1998 Jun; 9(2):161-70. PubMed ID: 9681392
[TBL] [Abstract][Full Text] [Related]
29. Biological and clinical implications of herbal medicine and natural products for the treatment of inflammatory bowel disease.
Guo BJ; Bian ZX; Qiu HC; Wang YT; Wang Y
Ann N Y Acad Sci; 2017 Aug; 1401(1):37-48. PubMed ID: 28891095
[TBL] [Abstract][Full Text] [Related]
30. Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.
Okazaki K; Nakase H; Watanabe N; Tabata Y; Ikada Y; Chiba T
J Gastroenterol; 2002 Nov; 37 Suppl 14():44-52. PubMed ID: 12572865
[TBL] [Abstract][Full Text] [Related]
31. Immunoregulatory Pathways Involved in Inflammatory Bowel Disease.
Fonseca-Camarillo G; Yamamoto-Furusho JK
Inflamm Bowel Dis; 2015 Sep; 21(9):2188-93. PubMed ID: 26111210
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic implications of interleukin-10 in inflammatory bowel disease.
Shirachi A
Kurume Med J; 1998; 45(1):63-7. PubMed ID: 9658753
[TBL] [Abstract][Full Text] [Related]
33. [Immunopathogenesis of inflammatory bowel diseases].
Neurath MF; Schürmann G
Chirurg; 2000 Jan; 71(1):30-40. PubMed ID: 10662999
[TBL] [Abstract][Full Text] [Related]
34. Pathway-based approaches to the treatment of inflammatory bowel disease.
Bamias G; Pizarro TT; Cominelli F
Transl Res; 2016 Jan; 167(1):104-15. PubMed ID: 26408803
[TBL] [Abstract][Full Text] [Related]
35. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).
Niessner M; Volk BA
Clin Exp Immunol; 1995 Sep; 101(3):428-35. PubMed ID: 7664489
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease.
Rose-John S; Mitsuyama K; Matsumoto S; Thaiss WM; Scheller J
Curr Pharm Des; 2009; 15(18):2095-103. PubMed ID: 19519447
[TBL] [Abstract][Full Text] [Related]
37. Cytokine production profile in intestinal mucosa of paediatric inflammatory bowel disease.
Vitale S; Strisciuglio C; Pisapia L; Miele E; Barba P; Vitale A; Cenni S; Bassi V; Maglio M; Del Pozzo G; Troncone R; Staiano A; Gianfrani C
PLoS One; 2017; 12(8):e0182313. PubMed ID: 28797042
[TBL] [Abstract][Full Text] [Related]
38. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease.
Schreiber S; Heinig T; Thiele HG; Raedler A
Gastroenterology; 1995 May; 108(5):1434-44. PubMed ID: 7729636
[TBL] [Abstract][Full Text] [Related]
39. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
Vyas SP; Goswami R
Front Immunol; 2018; 9():1139. PubMed ID: 29881387
[TBL] [Abstract][Full Text] [Related]
40. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD).
Duchmann R; Kaiser I; Hermann E; Mayet W; Ewe K; Meyer zum Büschenfelde KH
Clin Exp Immunol; 1995 Dec; 102(3):448-55. PubMed ID: 8536356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
